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ComorbiditiesAutism spectrum disorder (ASD) affects a signiﬁcant number of individuals in the United States, with the prev-
alence continuing to grow. A signiﬁcant proportion of individuals with ASD have comorbid medical conditions
such as epilepsy. In fact, treatment-resistant epilepsy appears to have a higher prevalence in children with ASD
than in children without ASD, suggesting that current antiepileptic treatments may be suboptimal in controlling
seizures in many individuals with ASD. Many individuals with ASD also appear to have underlying metabolic
conditions. Metabolic conditions such as mitochondrial disease and dysfunction and abnormalities in cerebral
folate metabolism may affect a substantial number of children with ASD, while other metabolic conditions
that have been associated with ASD such as disorders of creatine, cholesterol, pyridoxine, biotin, carnitine, γ-
aminobutyric acid, purine, pyrimidine, and amino acidmetabolism and urea cycle disorders have also been asso-
ciatedwith ASDwithout the prevalence clearly known. Interestingly, all of thesemetabolic conditions have been
associatedwith epilepsy in childrenwith ASD. The identiﬁcation and treatment of these disorders could improve
the underlyingmetabolic derangements and potentially improve behavior and seizure frequency and/or severity
in these individuals. This paper provides an overview of these metabolic disorders in the context of ASD and dis-
cusses their characteristics, diagnostic testing, and treatment with concentration on mitochondrial disorders. To
this end, this paper aims to help optimize the diagnosis and treatment of children with ASD and epilepsy.
This article is part of a Special Issue entitled “Autism and Epilepsy”.
© 2014 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Autism spectrum disorders (ASDs) are a group of behaviorally
deﬁned neurodevelopmental disorders with lifelong consequences.
They are deﬁned by impairments in communication and social interac-
tion along with restrictive and repetitive behaviors [1]. Autism spec-
trum disorder is now estimated to affect 1 out of 68 individuals in the
United States, with approximately four times more males than females
being affected [2]. Although ASD is behaviorally deﬁned, children with
ASD also have many co-occurring medical conditions such as gastroin-
testinal abnormalities [3], seizures and epilepsy [4], attention deﬁcits
[5], anxiety [6], and allergies [7], just to name a few.
One of the most signiﬁcant comorbidities associated with ASD
that causes signiﬁcant disability is epilepsy. A number of studies suggest
that epilepsy affects a high proportion of individuals with ASD. Indeed,
the reported prevalence of epilepsy in ASD ranges from 5% to 38%,tal Research Institute, Slot 512-
1 501 364 4662; fax: +1 501
This is an open access article under twhich is clearly higher than the 1%–2% prevalence in the general child-
hood population [8–12]. In addition, the prevalence of treatment-
resistant epilepsy is believed to be higher in children with ASD than in
the general childhood population [13]. Interestingly, recent reviews
note shared cognitive symptoms in epilepsy andASD, suggesting a com-
mon etiopathology [14], especially when ASD coexists with intellectual
disability [15].
The great preponderance of ASD research has concentrated on ge-
netic causes of ASD [16], despite the fact that inherited single gene
and chromosomal defects are only found in the minority of ASD
cases [17]. However, unlike idiopathic ASD, many genetic syndromes
that have a high prevalence of ASD also frequently have a high incidence
of epilepsy [18], and gene mutations associated with ASD are also fre-
quently associated with epilepsy [19]. Epilepsy also frequently co-
occurs with ASD in individuals who manifest metabolic abnormalities
such as abnormalities in mitochondrial metabolism [16] as well as
abnormalities in the regulation of essential metabolites such as fo-
late [20,21], cholesterol [22], and branched-chain amino acid [23]. One
interesting aspect of metabolic disorders in relation to ASD is that
some children with ASD have clear classic inborn-inherited errors of
metabolism, while perhaps more have metabolic abnormalities thathe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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abnormalities.
Several reviews have described some of the classic inborn-inherited
errors of metabolism that are associated with ASD [17,24]. Other re-
views have taken a broader view by including metabolic disorders
that do not necessarily have a clear genetic basis [20,25–27]. However,
these reviews have not concentrated onmetabolic abnormalities associ-
ated with ASD with respect to epilepsy. The fact that metabolic disor-
ders are associated with ASD suggests that, in some individuals, ASD
symptoms may arise from systemic abnormalities rather than from ab-
normalities speciﬁcally localized to the brain.
Identifying the metabolic abnormalities associated with ASD, espe-
cially for individuals with ASD who have comorbid epilepsy, is im-
portant as clarifying the underlying comorbid condition that may be
causing both the epilepsy and ASD can potentially lead to optimizing
treatment options in order to improve outcomes for individuals with
ASD as well as their families. In addition, since many metabolic path-
ways arewell understood, identifyingmetabolic defects can lead to aug-
menting standard epilepsy treatment with known or novel treatments
[4]. Furthermore, by understanding metabolic and genetic biomarkers
that can identify these disorders, itmight be possible to detect these dis-
orders early in life, even prenatally, so treatment can be started at the
earliest possible time, potentially before ASD symptoms or epilepsy de-
velops, in order to improve long-term outcome.
Given the fact that metabolic disorders may be amenable to treat-
ment, it is of paramount importance that physicians are aware of
the clinical features that are indicative of a metabolic disorder and ap-
propriately investigate patients with suggestive presentations. Howev-
er, unlike many diseases, metabolic disorders may not have particular
classic presentations, so basing a diagnostic strategy on the search for
one or two speciﬁc key symptoms is inappropriate. For example, pa-
tients withmitochondrial disorders can presentwith a variety of prima-
ry manifestations including neurologic, muscular, multisystemic, or
psychiatric. Thus, it is essential for the clinician to become sensitive to
the variety of potential symptoms and the patterns to which the symp-
tomsmanifest. This is of signiﬁcant importance when patients manifest
primary psychiatric symptomatology as such disorders are classically
diagnosed based on symptoms rather than on biochemical, metabolic,
or neuroimaging evaluations. Identifying an individual with a psychiat-
ric disorder with underlying metabolic abnormalities can signiﬁcantly
positively alter therapeutic management [28,29].
This article reviews the metabolic syndromes that are associated
with individuals with ASD and comorbid epilepsy. As many of these
syndromes are rather rare, themore rare syndromes are discussed brief-
ly. However, mitochondrial disease will be discussed in detail as it is of
particular interest in childrenwith ASD since it is being increasingly rec-
ognized as a cause of epilepsy in individuals with ASD [4,25] and those
without ASD [30–32] and novel treatments are being developed for mi-
tochondrial disease whichmay improve therapeutic options [33,34]. To
help better understand some of themetabolic abnormalities underlying
epilepsy and ASD, we will discuss the animal models of ASD that mani-
fest epilepsy and metabolic abnormalities. Finally, to facilitate the clini-
cal application of the information presented in the article, we discuss an
approach to diagnosing metabolic abnormalities in individuals with
ASD and epilepsy.1.1. Metabolic disorder associated with epilepsy in autism spectrum
disorder
Table 1 outlines the metabolic disorders associated with ASD and
comorbid epilepsy. This table organizes the metabolic disorders into
several categories, including disorders of energy, cholesterol, vitamin,
γ-aminobutyric acid (GABA), purine, pyrimidine, and amino acid me-
tabolism and urea cycle disorders. The prominent symptoms for each
disorder, not including ASD and epilepsy, along with the diagnostictests used to identify the disorder are outlined. Each disorder will be
reviewed within its category below.
1.1.1. Disorders of energy metabolism
Several disorders affecting energymetabolismhave been document-
ed in ASD, including mitochondrial disorders and creatine deﬁciency
syndromes. The prevalence of mitochondrial abnormalities in ASD
appears to be unusually high compared with that of typically develop-
ing individuals [25], and mitochondrial abnormalities have been impli-
cated in epilepsy in individuals without ASD, especially in individuals
with treatment-resistant [31] and temporal lobe [32] epilepsies. Mito-
chondrial abnormalities in relationship to ASD will be discussed in
more detail in a separate section below, while creatine deﬁciency syn-
dromes are discussed immediately below.
Creatine is synthesized in the liver and kidney and is transported
through the blood to high-energy demand tissues, such as the brain
and skeletal muscle, where it is actively transported into the
tissue against a large concentration gradient by the sodium/chloride-
dependent transporter known as CrT1 which is coded by the SLC6A8
gene. Once in tissues, creatine is phosphorylated by creatine kinase to
phosphocreatine, the main energy storage molecule of the cell, using
adenosine triphosphate (ATP). Without creatine, phosphocreatine can-
not be produced, and cells will become rapidly depleted in energy.
Disorders of creatine metabolism have been reported in children
with ASD and epilepsy [35,36]. Three inborn disorders of creatine
metabolism, collectively known as the creatine deﬁciency syndromes,
have been described since 1994. Two disorders involve deﬁciencies in
enzymes responsible for creatine production, arginine:glycine amidino-
transferase (AGAT), and S-adenosyl-L-methionine:N-guanidinoacetate
methyltransferase (GAMT), while the third disorder involves a deﬁcien-
cy in the creatine transporter.
The general presentation of children with disorders of creatine me-
tabolism includes developmental delay, regression, ASD features, men-
tal retardation, receptive and expressive language disorders, dyskinesia,
and seizures [37]. The severity of the symptoms depends on the speciﬁc
disorder. Individualswith GAMTdeﬁciency are themost severely affect-
ed, with almost invariable development of ASD and seizures, severe de-
lays in language, andmagnetic resonance imaging (MRI) abnormalities.
Individuals with creatine transporter disorder demonstrate a milder
phenotype, while children with AGAT deﬁciency demonstrate the
mildest phenotype [37]. Creatine transporter deﬁciency is an X-linked
recessive disorder, so a family history of X-linked mental retardation
is supportive of the diagnosis. Several reports suggest that creatine de-
ﬁciency disorders can be treated with high-dose creatine monohydrate
and a diet containing speciﬁc amino acids [38,39].
1.1.2. Disorders of cholesterol metabolism
Smith–Lemli–Opitz syndrome (SLOS) is a congenital disorder caused
by mutations in both DHCR7 genes, the genes that encode the Δ-7-
dehydrocholesterol reductase enzyme, a precursor step for the produc-
tion of cholesterol. Metabolically, children with SLOS demonstrate
elevated concentrations of 7-dehydrocholesterol and reduced choles-
terol concentrations in the blood. Interestingly, 50%–75% of children
with this disorder meet the criteria for ASD [40,41]. This disorder
is characterized by low birth weight, failure to thrive, poor feeding, ec-
zema, seizures, and congenital structural abnormalities of the heart,
gastrointestinal tract, genitalia, kidney, limbs, face, and brain [40,41].
Treatment with cholesterol supplementation in children with SLOS
has been reported to improve ASD and associated behavioral symptoms
in a case report [42], case series [43], and prospective cohorts [44,45],
especially in young children [46], but the effectiveness of such treat-
ment in seizure control has not been studied. This disorder can be diag-
nosed by measuring 7-dehydrocholesterol and cholesterol levels or by
DHCR7 sequencing. It is important not to rely on cholesterol levels
alone to diagnose SLOS as depressed levels of cholesterol are rather
common in children with ASD who do not have SLOS [22].
Table 1
Metabolic disorders associated with epilepsy and autism spectrum disorder.
Disorder Clinical features Diagnostic testing
Disorders of energy metabolism
Mitochondrial disease Developmental regression, gross motor delay, fatigability,
ataxia, and gastrointestinal abnormalities
• Fasting serum lactate, pyruvate, acylcarnitine,
amino acids, and urine organic acids
Creatine metabolism disorder Developmental regression, mental retardation, dyskinesia,
and family history of x-linked mental retardation
• Magnetic resonance spectroscopy
• Urine and serum creatine and guanidinoacetic acid
Disorders of cholesterol metabolism
Smith–Lemli–Opitz syndrome Low birth weight, failure to thrive, poor feeding, eczema,
and congenital structural abnormalities of the heart,
gastrointestinal tract, genitalia, kidney, limbs, face, and brain
• Blood 7-dehydrocholesterol and cholesterol
• DHCR7 sequencing
Disorders of cofactor (vitamin) metabolism
Cerebral folate deﬁciency Ataxia, pyramidal signs, acquired microcephaly, dyskinesias,
and visual and hearing loss
• Folate receptor alpha autoantibody
• Cerebrospinal ﬂuid 5-methyltetrahydrofolate
Pyridoxine-dependent and
pyridoxine-responsive seizures
Mental retardation, breath-holding, aerophagia, and
self-injurious behavior
• Pyridoxine trial
• Plasma and cerebrospinal ﬂuid pipecolic acid
• Urine α-aminoadipic semialdehyde
• ALDH7A1 sequencing
Biotinidase deﬁciency Developmental delays, seborrheic dermatitis, alopecia,
feeding difﬁculties, vomiting, diarrhea, brain atrophy, and
ataxia
• Biotinidase activity
• BTD gene sequencing
Carnitine biosynthesis deﬁciency Nondysmorphic male–male siblings with autism spectrum disorder • Plasma and/or urine 6-N-trimethyllysine,
3-hydroxy-6-N-trimethyllysine, and γ-butyrobetaine.
Disorders of γ-aminobutyric acid metabolism
Succinic semialdehyde dehydrogenase
deﬁciency
Global developmental delay, myoclonus, hallucinations,
ataxia, choreoathetosis, and dystonia
• Urine gamma-hydroxybutyric acid
Disorders of pyrimidine and purine metabolism
Adenylosuccinate lyase deﬁciency Global developmental delay, microcephaly, distinct facies,
growth retardation, mental retardation, cerebellar vermis
hypoplasia, brain atrophy, excessive laughter, and extreme
happiness
• Urine and/or cerebrospinal ﬂuid succinyladenosine
Nucleotidase-associated PDD Hyperactivity, compulsiveness, speech abnormalities, ataxia,
abnormal gait, and frequent infections
• Urine uridine
Hyperuricosuric autism Altered sensory awareness, ataxia, and ﬁne motor deﬁcits • 24-hour urine urate
Phosphoribosylpyrophosphate synthetase
deﬁciency
Developmental delay and ataxia • Urine uric and orotic acids
• Complete blood count
Disorders of amino acid metabolism
Phenylketonuria Global developmental delay, mental retardation, microcephaly,
spasticity, ataxia, poor growth, poor skin pigmentation, and
aggressive behavior
• Serum phenylalanine
Branched-chain ketoacid dehydrogenase
kinase deﬁciency
Intellectual disability and consanguinity • Plasma and cerebrospinal ﬂuid branched-chain
amino acids
Altered tryptophan metabolism No speciﬁc features besides autism spectrum disorder • Reduced cellular generation of nicotinamide
adenine dinucleotide
Urea cycle disorders
Urea cycle disorder Protein intolerance, temperature instability, ataxia, episodic
somnolence and lethargy, cyclic vomiting, and psychosis
• Plasma ammonia and amino acids
• Urinary orotic acid
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Disorders of vitaminmetabolism that have been reported in children
with ASD and epilepsy include disorders of folate, pyridoxine, biotin,
and carnitine metabolism, each of which will be reviewed below.
Several folate metabolism abnormalities have been linked to ASD.
Polymorphisms in key folate pathway enzymes such asmethylenetetra-
hydrofolate reductase [47–56], dihydrofolate reductase [57], and the re-
duced folate carrier [55] have been associated with ASD but have not
speciﬁcally been associatedwith epilepsy in individualswithASD. How-
ever, childrenwith cerebral folate deﬁciency (CFD) are commonly diag-
nosed with epilepsy and/or ASD [58–60]. Folate is transported across
the blood–brain barrier by an energy-dependent receptor-mediated
system that utilizes the folate receptor alpha (FRα) [61]. Autoantibodies
that can bind to the FRα and greatly impair its function have been linked
to CFD [58]. Since this transport system is energy-dependent, a wide
variety of mitochondrial diseases [26,62–68] and novel forms of mito-
chondrial dysfunction related to ASD [69] have been associated with
CFD. Recently, Frye et al. [20] reported that 75% of 93 children withASD were positive for one of the two FRα autoantibodies. The high
rate of FRα autoantibody positivity was conﬁrmed by a recent study
from Belgium that measured the FRα blocking autoantibody. This
study found that 47% of 75 children with ASD were positive for the
FRα blocking autoantibody comparedwith3%of 30 controlswith devel-
opmental delays but not autism [70]. Many children with ASD and CFD
have marked improvement in clinical status when treated with folinic
acid — a reduced form of folate that can cross the blood–brain barrier
using the reduced folate carrier rather than the FRα transport system
[20,58,59,71]. Folate receptor alpha autoantibody testing can be per-
formed clinically, but a lumbar puncture to measure the cerebrospinal
ﬂuid concentration of 5-methyltetrahydrofolate is the gold standard di-
agnostic test for CFD.
Pyridoxine and its primary biologically active form pyridoxal-5-
phosphate play major roles in the proper function of over 60 enzymes.
Pyridoxal-5-phosphate is a cofactor for glutamic acid decarboxylase,
the enzyme that metabolizes glutamic acid to GABA. Usually, pyridox-
ine-dependent seizures and pyridoxine-responsive seizures present
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clinical response to pyridoxine therapy [72,73]. Themajority of pyridox-
ine-dependent seizures appear to result from a deﬁciency in the en-
zyme α-aminoadipic semialdehyde dehydrogenase associated with
mutations in the ALDH7A1 (antiquitin) gene [74,75]. These mutations
result in the excess production of Δ1-piperideine-6-carboxylate, a com-
poundwhich complexeswith and depletes pyridoxal-5-phosphate [74].
Pyridoxal-5-phosphate depletion reduces glutamic acid decarboxylase
activity, resulting in a reduction in GABA synthesis [74,76,77]. Although
early-onset intractable tonic–clonic seizures are the usual presentation,
late-onset seizures [78–80] and other seizure types [81–83] have been
described. It has been suggested that pyridoxine-responsive seizures
may be a clinical entity distinct from pyridoxine-dependent seizures
[84]. In children with ASD, several studies have reported signiﬁcant
improvement in behavior and cognition attributable to combined ther-
apy with magnesium and pyridoxine [85–88], but others have not been
able to document such a response [89,90]. There has been one case re-
port of ASD associated with severe mental retardation, aerophagia,
breath-holding, self-injury, and pyridoxine-dependent seizures [91].
According to the report, pyridoxine improved seizures but did not im-
prove ASD features. When suspected, pyridoxine-dependent seizures
can be diagnosed by measuring plasma and/or cerebrospinal ﬂuid
concentration of pipecolic acid, measuring urine concentrations of α-
aminoadipic semialdehyde, or sequencing the ALDH7A1 gene. A pyri-
doxine trial can also be useful clinically.
Biotinidase deﬁciency is caused by mutations in both BTD genes
which results in a deﬁciency of the biotinidase enzyme, an enzyme that
is needed to recycle biotin, an essential cofactor for several carboxylase
enzymes. Typical onset is early in life, between the 1st and 24th months
of life. Symptoms include seizures, developmental delays, skin rash, seb-
orrheic dermatitis, alopecia, feeding difﬁculties, vomiting, diarrhea, brain
atrophy, and ataxia. Metabolic testing can demonstrate elevated blood
lactate and ammonia as well as abnormal urine organic acids including
elevations in β-hydroxyisovalerate, β-methylcrotonylglycine, β–
hydroxypropionate, and methylcitrate. Standard treatment is 10 mg of
daily biotin. The one reported child with ASD and partial biotinidase de-
ﬁciency did not respond to treatment, although itwas believed that ASD
was prevented in his younger brother who also manifested symptoms
of partial biotinidase deﬁciency [92]. Biotinidase deﬁciency is character-
ized by neurodevelopment problems and seborrheic dermatitis in chil-
dren. Biotinidase activity can be tested clinically, and any suspicious
case should be conﬁrmed by BTD gene sequencing.
Recently, a defect in the carnitine biosynthesis pathway was de-
scribed in seven children with ASD, one of whom also had epilepsy
[93]. This defect in exon 2 of the X chromosome TMLHE gene encodes
the ﬁrst enzyme in the carnitine biosynthesis pathway, speciﬁcally 6-
N-trimethyllysine dioxygenase. Interestingly, this genetic change was
not more common in children with ASD than in control children overall
but wasmore common in probands from families withmale–malemul-
tiplex ASD comparedwith controls, suggesting that thiswas a risk factor
for these families rather than a causative metabolic disease. Carnitine
deﬁciency appears to be common in the wider populations with ASD,
but childrenwith ASD and carnitine deﬁciency have not beenwell char-
acterized regarding their ASD and medical symptoms such as epilepsy
[94]. Given the lack of carnitine genes found to be directly related to
ASD, some authors have hypothesized that carnitine deﬁciency in ASD
may be secondary to mitochondrial disease or dysfunction [25,95],
while others have suggested that carnitine metabolism abnormalities
may be related to the overproduction of short-chain fatty acids resulting
from imbalances in enteric bacteria [96,97].
1.1.4. Disorders of γ-aminobutyric acid metabolism
First described in 1981, succinic semialdehyde dehydrogenase
deﬁciency is a rare disorder of GABAmetabolism that results fromamu-
tation in both ALDH5A1 genes [98]. Since the enzyme is partially re-
sponsible for the degradation of GABA, brain GABA levels are elevated,and GABA is degraded by an alternative pathway that produces γ-
hydroxybutyric acid. Elevated γ-hydroxybutyric acid results in many
of the neurologicalmanifestations of this disorder. Positron emission to-
mography studies suggest that elevated GABA levels downregulate
brain GABAA receptors [99]. Symptom onset commonly occurs before
1 year of age with global developmental delay, hypotonia, hyporeﬂexia,
ASD features, seizures, ataxia, choreoathetosis, dystonia, myoclonus,
strabismus, nystagmus, retinitis, disc pallor, and oculomotor apraxia
[100,101]. Magnetic resonance imaging can demonstrate increased T2
signal in the basal ganglia, subcortical whitematter, brainstem, and cer-
ebellum [102,103]. Metabolically, the urine, serum, and cerebrospinal
ﬂuid may demonstrate an elevation in 4-hydroxybutyric acid, but this
highly volatile compound can be difﬁcult to measure. Sequencing the
ALDH5A1 gene can conﬁrm the diagnosis.
1.1.5. Disorders of pyrimidine and purine metabolism
Children with ASD and comorbid seizures have been described to
have disorders of purine and pyrimidine metabolism. These in-
clude both classic inborn-inherited disorders of metabolism, such as
adenylosuccinate lyase deﬁciency and phosphoribosylpyrophosphate
synthetase deﬁciency, as well as novel disorders of purine metabolism
that do not have a clearly genetic basis.
Adenylosuccinate lyase deﬁciency is a rare disorder of de novo pu-
rine synthesis that results in the accumulation of succinyl purines
[104,105]. Patients have a unique behavioral phenotype including
excessive laughter, a very happy disposition, and stereotyped move-
ments mimicking Angelman syndrome [106]. Patients show a variable
combination of mental retardation, epilepsy, ASD features, and cerebel-
lar vermis hypoplasia [104,105]. This disorder can be diagnosed using
the Bratton–Marshall assay to measure succinylaminoimidazole
carboxamide riboside and succinyladenosine concentration in the
urine and/or cerebrospinal ﬂuid.
One patient with developmental delay and ataxia as well as seizures
and ASD features has been described with phosphoribosylpyro-
phosphate synthetase deﬁciency [107]. Metabolic abnormalities in-
cluded decreased uric acid and increased orotic acid excretion and
megaloblastic anemia and erythrocyte phosphoribosylpyrophosphate
synthetase activity that was 10% of normal. Treatment with adrenocorti-
cotrophic hormone reportedly increased erythrocyte phosphoribosyl-
pyrophosphate synthetase activity and improved behavior and seizures.
Others have described some novel abnormalities in the purine path-
way. In 1993, hyperuricosuric autism was described in which 24-hour
urine urate was above the normal range and half of the patients had co-
morbid seizures [107]. Although it was believed that themetabolic basis
was likely to be an abnormality of purine nucleotide interconversion, no
abnormality in enzyme activity could be detected in ﬁbroblasts, and no
genetic basis could be identiﬁed. A low-purine diet and allopurinol may
improve behavior and seizures in these patients.
In 1997, Page et al. [108] described four patients with ASD, seizures,
immune system abnormalities, and a decrease in urinary urate. This
disorder was later termed nucleotidase-associated pervasive develop-
mental disorder [107]. Fibroblasts from the patients demonstrated
decreased incorporation of uridine into nucleotides and an increase in
cytosolic-5′-nucleotidase activity, suggesting an increase in nucleotide
catabolic activity. All patients treated with oral pyrimidine nucleoside
or nucleotide compounds showed a remarkable improvement in
speech, behavior, and seizure activity. No genetic basis was found for
this disorder.
1.1.6. Disorders of amino acid metabolism
Disorders in the metabolism of phenylalanine, branched-chain
amino acids, and tryptophan have been described in children with
ASD and comorbid epilepsy and will be reviewed in this section.
Phenylketonuria (PKU), for the most part, has been eliminated in
the developed world. Phenylketonuria is an autosomal recessive
inborn error of phenylalanine metabolism resulting from deﬁciency of
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chromosome 12q23.2. Newborn screening programs identify children
with PKU at birth, allowing the implementation of speciﬁc dietary inter-
vention. With good adherence to diet, children born with PKU can be
expected to lead a normal life [109]. However, children with PKU who
go untreated or who do not adhere to the diet adequately may demon-
strate poor growth, poor skin pigmentation, microcephaly, seizures,
spasticity, ataxia, aggressive behavior, hyperactivity, ASD features, glob-
al developmental delay, and/or severe intellectual impairment. For
example, Baieli et al. [110] found that no childrenwith classic PKU iden-
tiﬁed as neonatesmet the criteria for ASD, whereas 6% of thosewith late
diagnosed classic PKU were identiﬁed with ASD. The prevalence of sei-
zures and epilepsy is dependent on metabolic control [111]. Gross
et al. [112] demonstrated that children who started treatment later
were more likely to have seizures and mental retardation.
Recently an inactivating mutation in the branched-chain ketoacid
dehydrogenase kinase was described to be associated with autism, epi-
lepsy, and intellectual disability in three families with two children each
who were products of ﬁrst-cousin consanguinity [23]. In this disorder,
phosphorylation-mediated inactivation of branched-chain ketoacid de-
hydrogenase is deﬁcient, leading to abnormally low levels of branched-
chain amino acids. Behavioral and neurological deﬁciencies were re-
versed in a mouse model of this disorder but not in the patients.
Using Biolog (Hayward, CA) phenotype microarrays, a recent study
demonstrated a reduced production of nicotinamide adenine dinucleo-
tide in cell lines derived from patients with syndromic ASD and from
those with nonsyndromic ASD when tryptophan was provided as a
sole carbon source, suggesting an abnormality in tryptophan metabo-
lism [113]. Further studies of patients with ASD demonstrated a reduc-
tion in the expression of several tryptophan pathway enzymes,
including TPH2, a gene that has been linked to both ASD [114,115]
and epilepsy [116]. Altered central tryptophan metabolism has also
been identiﬁed in a mouse model of progressive myoclonic epilepsy
[117,118]. The exact biological mechanism by which tryptophan is
linked to bothASDand epilepsy is not clear, but there aremany possibil-
ities since it is an essential precursor of many neurotransmitters includ-
ing serotonin, kynurenic acid, and quinolinic acid, and the critical
mitochondrial energy carrier nicotinamide adenine dinucleotide.
1.1.7. Urea cycle disorders
The urea cycle disposes of nitrogenous waste derived from the
breakdown of protein. The key sign of a urea cycle disorder is a large el-
evation in blood ammonia after a high-protein meal or during times of
illness or physiological stress. Symptoms can range from decreased ap-
petite to cyclical vomiting to lethargy or, in severe cases, coma. In some
cases, patientsmay self-select low-protein diets tominimize symptoms.
Psychosis, seizures, and pyramidal signs develop over time. Two cases of
childrenwith urea cycle disorders, onewith ornithine transcarbamylase
deﬁciency and arginase deﬁciency [119] and another with carbamyl
phosphate synthetase deﬁciency [120], have been reported. Treatment
focused on reducing ammonia through a low-protein diet and ammonia
binders and supplementation with speciﬁc amino acids and various vi-
tamin supplements [121]. Improvement in ASD symptoms has been re-
ported with treatment.
1.2. Mitochondrial dysfunction associatedwith epilepsy in autism spectrum
disorder
A recent meta-analysis found that 5% of children with ASD met
the criteria for classic mitochondrial disease, while as many as 30% of
children with ASD may manifest mitochondrial dysfunction [25].
Other studies suggested that 30% to 50% of children with ASD have bio-
markers consistent with mitochondrial dysfunction [122,123], and the
prevalence of abnormalmitochondrial function in immune cells derived
from children with ASD is exceedingly high [124,125]. Mitochondrial
dysfunction has been demonstrated in the postmortem ASD brain[126–131] and in animalmodels of ASD [132]. Novel types ofmitochon-
drial dysfunction have been described in children with ASD [69,96,133]
and in cell lines derived from children with ASD [134,135]. Several
studies suggest that children with ASD and mitochondrial dysfunction
have more severe behavioral and cognitive disabilities compared with
childrenwith ASDwithoutmitochondrial dysfunction [136–138]. Inter-
estingly, a recent review of all of the known published cases of mito-
chondrial disease and ASD demonstrated that only about 25% have a
known genetic mutation that can account for their mitochondrial dys-
function [122].
A meta-analysis found that, overall, 41% of children with ASD and
documented mitochondrial disease are reported to have seizures [25].
This perhaps should not be surprising asmitochondrial dysfunction has
been implicated in seizures and epilepsy, especially in therapy-resistant
[31] and temporal lobe [32] epilepsies. The association between ASD
and seizures in children with mitochondrial disease was ﬁrst described
as part of the HEADD (hypotonia, epilepsy, autism, and developmental
delay) syndrome [139]. These cases demonstrated deﬁciencies in com-
plexes I, III, and IV or large-scale mitochondrial deoxyribonucleic acid
(DNA) deletions. Further case reports and series have linked seizure
disorders in ASD with complex deﬁciencies, particularly complex III de-
ﬁciencies. For example, seizures have been reported in individuals with
complex III deﬁciency [140] and combined complex I + III deﬁciency
[141]. Since the electron transport chain (ETC) is the ﬁnal common
pathway for producing the common cellular energy carrier, adenosine
triphosphate (ATP), deﬁciencies in ETC function can have profound
effects on the production of energy at the cellular level. Interestingly,
mitochondrial dysfunction has been reported in many genetic syn-
dromes associated with ASD and epilepsy. For example, mitochon-
drial dysfunction has been reported in Rett syndrome [142–144],
PTEN haploinsufﬁciency [145], Phelan–McDermid syndrome [146],
15q11-q13 duplication syndrome [140,147], Angelman syndrome
[148], Septo-optic dysplasia [149], and Down syndrome [150,151].
Thus, mitochondrial dysfunction may underlie the phenotype of ASD
with epilepsy, regardless of the underlying cause.
Some of the novel forms of mitochondrial dysfunction associated
with ASD have a high prevalence of epilepsy. Eighty percent of the ﬁve
children described with complex IV overactivity manifested either gen-
eralized seizures or subclinical epileptiform discharges on overnight
electroencephalogram [69], and the case with complex I overactivity
had complex partial seizures and frequent bursts of predominant-
ly left-sided multispike–wave discharges on electroencephalogram
[133]. Another unique form of mitochondrial dysfunction in ASD ap-
pears to be associated with an abnormal increase in a particular pattern
of short and long acylcarnitines [96]. This pattern of metabolic abnor-
malities parallels a rodentmodel of ASD in which these samemetabolic
abnormalities are induced by propionic acid [97]. Detailed study of chil-
dren with this biomarker reveals a unique change in ETC and citric acid
cycle function consistent with excess metabolic ﬂux of propionic acid
[96]. Theoretically, propionic acid can be overproduced by the overrep-
resented species of Clostridia found in the gastrointestinal tract of chil-
dren with ASD [152,153]. Given that propionic acid is a short-chain
fatty acid that can complex with L-carnitine, increased propionic acid
production could also explain the relatively common carnitine deﬁcien-
cy documented in children with ASD [96,97,153]. The propionic rodent
model of ASD demonstrates epileptiform-like spikes in the hippocam-
pus, neocortex, and basal ganglia, with discharges in the basal ganglia
associated with measurable behavioral abnormalities [97]. However,
in the published case series of children with ASD, only 27% demonstrat-
ed abnormalities on overnight video electroencephalogram, and only
10% reported a history of seizures [96]. Clearly, further research is need-
ed to further elucidate the correspondence between novel forms of mi-
tochondrial dysfunction and epilepsy in ASD.
Abnormalities in mitochondrial function can lead to abnormal
development in brain circuits, resulting in both neurodevelopmental
disorders and epilepsy through several mechanisms. Mitochondria are
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body, especially the brain. Abnormalities in mitochondrial biomarkers
found peripherally have also been found in the brains of individuals
with ASD [131]. Thus, it is very likely that changes in mitochondrial
function in the brain affect neural transmission and function in children
with ASD. This could occur through several mechanisms. Neural synap-
ses are areas of high energy consumption [154] and are especially
dependent on mitochondrial function [155]. Mitochondria are concen-
trated in the dendritic and axonal termini where they play an important
role in ATP production, calcium homeostasis, and synaptic plasticity
[156,157]. Mitochondrial dysfunction can compromise neurons with
high ﬁring rates, such as GABAergic interneurons [158]. Reduced
GABAergic transmission may be relevant in ASD as GABA neurons are
essential for the generation and synchronization of high-frequency
gamma rhythms — rhythms essential for high-level cortical processing
of sensory information and ‘binding’ that have been shown to be abnor-
mal in children with ASD [159]. The age range when autistic regression
typically occurs corresponds to a time when there is an overabundance
of cortical excitatory glutamatergic neurotransmitters and receptors
[160,161] and rapid brain growth [162]. Thus, this is a developmental
window in which mitochondrial energy production is pivotal. Given
the importance of glutamate and GABA transmission in the develop-
ment and progression of epilepsy, these same imbalances of glutamate
and GABA neurotransmission could result in seizures and epilepsy in
children with ASD [163,164].
Mitochondrial dysfunction is well known to result in increased
levels of reactive oxygen species. Reactive species can damage neural
tissue and interfere with neural transmission. Glutathione is the princi-
pal intrinsic molecule that protects cells against reactive species. Given
that glutathione levels in the brain are about 50-fold lower than those
in peripheral tissues, such as hepatocytes, neurons may be especially
sensitive to increases in reactive oxygen species [165]. Recent studies
have suggested that oxidative stress may be involved in the develop-
ment of epilepsy [166]. In fact, several studies have discussed the
use of antioxidants as a treatment for epilepsy [167,168], and several
groups have hypothesized that one of the mechanisms for seizure con-
trol with the ketogenic diet is through the improvement of oxidative
stress [169,170]. Interestingly, studies have demonstrated the connec-
tion between reactive oxygen species and mitochondrial dysfunction
in brain tissue from individuals with ASD [126]. This may be another
mechanism in which mitochondrial dysfunction and disease can lead
to the development of epilepsy in children with ASD.
Immune dysfunction has been implicated in the development of
epilepsy [171], and evidence of cellular and humoral immune dysfunc-
tion has been implicated in ASD [131,172]. In fact, the same autoanti-
bodies to neural antigens have been linked to both autism and
epilepsy [173,174]. This is signiﬁcant as mitochondrial dysfunction in
ASD has been repeatedly reported in immune cells [125,134,145] with
such mitochondrial dysfunction linked to abnormalities in immune
cell function [125]. In addition, abnormalities in microglia have been
linked to abnormal brain development in Rett syndrome [175], and
studies suggest that the immune system may be essential for synaptic
pruning during development [176]. Thus, abnormalities in immune
cell function as a result of mitochondrial dysfunction may also result
in seizures in children with ASD.
Another physiological abnormality that is becoming increasingly
recognized in both ASD and epilepsy is the dysregulation of calcium
[177,178]. Its relationship to ASD and epilepsy is best characterized by
the novel genetic disorder Timothy syndrome which includes arrhyth-
mias, particular dysmorphology, congenital heart disease, immune deﬁ-
ciency, hypoglycemia, ASD, and seizures [179]. Calcium regulation is
important not only in the regulation of the cell membrane potential,
where its dysregulation in cardiomyocytes causes arrhythmias, but
also within the cell where it regulates enzymes and transcription fac-
tors. Most interesting is the connection betweenmitochondrial function
and calcium. Mitochondria have a signiﬁcant role in the buffering ofcellular calcium having multiple calcium transporters. Many mitochon-
drial enzymes are regulated by calcium, resulting in cellular calciumﬂux
having both short-term and long-term consequences on mitochondrial
activity [180]. Evidence suggests that calcium plays a signiﬁcant role in
regulation of cellular bioenergetics, production of reactive oxygen
species, and induction of autophagy and apoptosis through its in-
teraction with the mitochondria at endoplasmic reticulum-speciﬁc
subdomains known as mitochondria-associated membranes [181,182].
Thus, abnormalities in cellular calcium regulation can have signiﬁcant
effects on mitochondrial function and have led some authors to point
out the possibility of mitochondrial dysfunction in neurological and
neurodevelopmental disorders associated with abnormalities in
calcium metabolism [178]. Thus, abnormalities in calcium metabolism
related to ASD and epilepsy provide another link to mitochondrial dys-
function in ASD and epilepsy.
Interestingly, treatments that are typically used for patientswithmi-
tochondrial disease have been shown to improve functioning in some
children with ASD [122]. Several studies, including two double-blind,
placebo-controlled studies [183,184], have reported improvements
in core and associated ASD behaviors with L-carnitine treatment
[140,141,183–188]. Two double-blind, placebo-controlled studies
using a multivitamin containing B vitamins, antioxidants, vitamin E,
and coenzyme Q10 reported various improvements in ASD symptoms
compared with placebo [189,190]. Several other antioxidants [90],
including vitamin C [191], methylcobalamin [192–194], N-acetyl-L-
cysteine [195–197], ubiquinol [198], and carnosine [199], have also
been reported to demonstrate signiﬁcant improvements in ASD behav-
iors. However, the effect of these treatments on seizures or epilepsy in
these children was not investigated in these studies.1.3. Animal models of autism and epilepsy
There are several models of ASD that also manifest epilepsy and
metabolic abnormalities. As mentioned above, the propionic rodent
model of ASD demonstrates mitochondrial, oxidative stress and lipid
abnormalities as well as epileptiform-like discharges in the brain [97,
153]. However, the majority of biochemical data from the rodent
model are derived from adult animals exposed to proprionic acid by
intraventicular injections, thereby limiting the generalizability and
translatability of the data. Despite this limitation, there appears to be
preliminary evidence of a corresponding ASD metabolic subgroup of
children with similar manifestations [96]. Ongoing animal studies
using prenatal and neonatal exposure to enteric metabolites demon-
strated the induction of ASD-like behaviors, lending support for the
validity of the adult animal model [200,201]. Several genetic models
of ASD syndromes in which epilepsy is common have demonstrated
mitochondrial dysfunction including Rett syndrome [142], PTEN
haploinsufﬁciency [145], and Angelman syndrome [148], while abnor-
malities in oxidative metabolism have been demonstrated in the Rett
syndrome mouse model [142]. Classic environmental exposure models
of ASD have also been shown to involve mitochondrial dysfunction as
ASD behaviors induced by prenatal valproic acid exposure have been
shown to be associated with reduced mitochondrial respiration [202].
A new rat model of ASD and ADHD, which has a predisposition toward
seizures, manifests aberrant lipid handling [203]. Interestingly, ASD-like
symptoms improved when the ketogenic diet, a metabolic diet with
therapeutic effect for both epilepsy and mitochondrial disorders, was
used therapeutically in several well-established mouse models of ASD
that demonstrate comorbid seizure susceptibility, including the BTBR
[204], EL [205], and prenatal valproic acid exposure [202] mouse
models. Indeed, understanding themetabolic abnormalities in these an-
imal models and how they correspond to children with ASD not only
will help us understand the pathophysiology in more detail but also
will allow treatment to be optimized on the animal models before
launching human clinical trials.
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There are several factors that make the diagnosis of metabolic dis-
ease difﬁcult, most prominently the heterogeneity of the presentation
of metabolic disorders. While many traditional diseases are diagnosed
by symptoms that are speciﬁc to the disease, it is unusual for metabolic
diseases to have speciﬁc symptoms. As an example,wewill considermi-
tochondrial disorders. Adult patients with mitochondrial disorders
often show obvious gross motor issues, including easy fatigability, my-
opathies, or cardiomyopathies, while muscular manifestations are
seen in a minority of patients with pediatric mitochondrial disease
[206], and it is actually unusual for children with mitochondrial disease
to present with characteristic hallmarks [207]. Indeed, in the pediatric
population, classic biochemical markers such as lactic acidosis andmus-
cle tissue histology such as ragged red ﬁbers are not commonly seen
with mitochondrial disease caused by well-established genetic muta-
tions [208]. This makes the diagnosis of metabolic disease rather differ-
ent from many classic diseases and requires a shift in the diagnostic
strategy. Indeed, many times, diagnosis is based on a diagnostic criteri-
on that indicates the probability of a metabolic disorder or a collection
of symptoms and biomarkers that are only suggestive of a metabolic
syndrome. In addition, many metabolic diseases associated with
neurodevelopmental disorders do not appear to have a simply clear ge-
netic ﬁngerprint. In the case of mitochondrial disease, two genomes, the
mitochondrial and the nuclear genome, as well as the interaction
between the two genomes, need to be considered. In addition, the mito-
chondrion is sensitive to damage from extrinsic environmental factors
as well as intrinsic factors that increase oxidative stress, thus raising the
possibility of acquired mitochondrial dysfunction [16,122,131,209,210].
We have some evidence of a clinical phenotype of mitochondrial
dysfunction in some children with ASD that may raise our index of sus-
picion in any particular patient. A recentmeta-analysis that reviewed all
of the cases of mitochondrial disease reported in children with ASD
noted an unusually high prevalence of regression, gastrointestinal dys-
function, and motor delays, as well as seizures, in children with ASD
and mitochondrial disease compared with the general population with
ASD [122]. Speciﬁc mitochondrial disease syndromes associated with
ASD have certain clinical symptoms that could be helpful in diagnosing
a mitochondrial disorder. The HEADD syndrome includes hypotonia
and developmental delays [139]. However, since the prevalence of hy-
potonia was not found to differ between children with ASD and mito-
chondrial disease and the general population with ASD, hypotonia
may not be a symptom speciﬁc enough to differentiate individuals
with ASDwithmitochondrial disease from thosewithoutmitochondrial
disease [122]. In a biomarker analysis, individuals with ASD whomani-
fested the unique elevations in short and long acylcarnitine abnormali-
ties showed a high rate of regression [123], consistent with others who
have demonstrated that the enteric gut bacteria that produce propionic
acid appear to be associated with regressive-type ASD [211,212]. This
preliminary biomarker analysis also found that the subset of children
with an elevation in the alanine-to-lysine ratio during screening for
metabolic disorders tended to have a diagnosis of epilepsy [123]. All of
the cases of children with complex I or IV overactivity and epilepsy or
subclinical epileptiform discharges demonstrated normal early devel-
opment followed by a substantial developmental regression with poor
developmental recovery despite therapeutic interventions [69,133].
Thus, reviewing the cases of mitochondrial dysfunction and epilepsy
associated with ASD does underscore two phenotypes that appear
to be associated with mitochondrial disease, either developmental de-
lays from early in life, particularly motor delays, or abrupt regression
with the onset of seizures. When these symptoms are found in a child
with ASD and seizures, an investigation of mitochondrial disease is
warranted.
Given the fact that childrenwith ASD can have a widemanifestation
of symptoms, usually affecting many systems other than the brain, and
that children with mitochondrial disease can have a wide variety ofsymptoms and biochemical ﬁndings [213,214], several reviews have
suggested that mitochondrial disease should be considered in all
children with ASD [26,122]. Recently, several algorithms outlining the
workup for mitochondrial disease in ASD have been published [26,27,
96,122]. Most importantly, it has been pointed out that given the low
prevalence of known genetic mutations associated with mitochondrial
disease in ASD and themany novel forms of mitochondrial disorders as-
sociated with ASD, a mitochondrial disease diagnostic criterion based
on symptoms and biochemical ﬁndings may bemore useful in the diag-
nostic workup of children with ASD than a diagnostic criterion more
speciﬁc to classic mitochondrial disease [26,27].
Other metabolic disorders associated with ASD and epilepsy appear
to have a much lower prevalence except for disorders that affect the
folate pathway, particularly the association with FRα autoantibodies
[20]. Thus, in addition to mitochondrial disease and dysfunction, abnor-
malities of folatemetabolism and FRα autoantibodies should be consid-
ered in all childrenwith ASD [20]. Childrenwith negative ﬁndings given
a workup for these disorders and/or those with treatment-resistant
epilepsy should undergo further investigation for other metabolic
disorders. Many of these disorders do not have speciﬁc clinical symp-
tomatology to point toward, while some clinical clues may help for
other disorders. For example, X-linked inheritance is seen in creatine
transporter disorder and certain urea cycle disorders, and consanguinity
has been noted in branched-chain ketoacid dehydrogenase kinase
deﬁciency; recurrent episodes of vomiting and lethargy, particularly
after a protein meal, are seen in urea cycle disorders; particular facial
dysmorphology is common in adenylosuccinate lyase deﬁciency and
Smith–Lemli–Opitz syndrome; movement disorders are seen in crea-
tine metabolism disorder, CFD, and succinic semialdehyde dehydroge-
nase deﬁciency; and recurrent infections are seen in disorders of
purine metabolism. Thus, it is difﬁcult to develop a speciﬁc diagnostic
algorithm to investigate these metabolic disorders systematically since
diagnosis requires careful consideration of the individual patient to
gather speciﬁc clues.
2. Discussion
We have reviewed all of the metabolic disorders that are associated
with ASD in which epilepsy has been reported to be a comorbid condi-
tion. Interestingly, all of the metabolic diseases associated with ASD ap-
pear to include cases of children with comorbid epilepsy. Thus, epilepsy
may be a common symptom of metabolic disorders and may be a clue
that a metabolic disorder may be underlying the etiology of the neuro-
developmental abnormalities in children with epilepsy and ASD. It is
also important to consider many of the metabolic disorders even
when genetic disorders are diagnosed. Indeed, CFD can coexist with
Rett syndrome [215], and mitochondrial dysfunction has been re-
ported in a wide variety of genetic disorders associated with ASD [140,
142–151]. In addition, CFD should be ruled out in the context of mito-
chondrial dysfunction as it has been shown to coexist with several mi-
tochondrial diseases [26,62–69].
One advantage of investigating and diagnosing metabolic disorders
is that treatments for many of these metabolic disorders are available
[4]. Preliminary studies suggest that there are a substantial number of
children with ASD with these metabolic abnormalities. For example,
mitochondrial dysfunction may be seen in 5% to 80% of children with
ASD [122–124], and FRα autoantibodies may be found in 47% [70] to
75% [20] of children with ASD. Clearly, further studies will be required
to clarify the percentages of these subgroups. As several studies have
suggested that treatment for thesemetabolic disorders can improve sei-
zures, this is an important consideration in the diagnosis and treatment
of epilepsy in children with ASD.
Many of themetabolic diseases described have only been reported in
case reports or case series, so the prevalence of these metabolic abnor-
malities in children with ASD and epilepsy is not fully known. Given
the small number of patients described with some disorders, it is not
154 R.E. Frye / Epilepsy & Behavior 47 (2015) 147–157always clear if epilepsy is strongly linked to the disorder or whether
the epilepsy simply coexists with the underlying neural dysfunction
that has resulted in the ASD features. Further studies will be needed to
determine the exact relationship between certain metabolic disorders,
ASD, and epilepsy. However, some disorders like mitochondrial disor-
ders are clearly prevalent in children with ASD and epilepsy and, thus,
deserve consideration during the diagnosticworkup. Clearly,many chil-
drenwith ASD and their familiesmay be able to beneﬁt from treatments
which are focused on addressing metabolic abnormalities.
Conﬂict of Interest
The authors declares no conﬂict of interest.
References
[1] APA. Diagnostic and statistical manual of mental disorders. 4th ed. Washington,
DC: American Psychiatric Association; 1994.
[2] Developmental Disabilities Monitoring Network Surveillance Year Principal I, Cen-
ters for Disease C, Prevention. Prevalence of autism spectrum disorder among chil-
dren aged 8 years — autism and developmental disabilities monitoring network,
11 sites, United States, 2010. MMWR Surveill Summ 2014;63:1–21.
[3] Chaidez V, Hansen RL, Hertz-Picciotto I. Gastrointestinal problems in children with
autism, developmental delays or typical development. J Autism Dev Disord 2013;
44:1117–27.
[4] Frye RE, Rossignol D, CasanovaMF, Brown GL, Martin V, Edelson S, et al. A review of
traditional and novel treatments for seizures in autism spectrum disorder: ﬁndings
from a systematic review and expert panel. Front Public Health 2013;1:31.
[5] Taurines R, Schwenck C, Westerwald E, Sachse M, Siniatchkin M, Freitag C. ADHD
and autism: differential diagnosis or overlapping traits? A selective review. Atten
Deﬁc Hyperact Disord 2012;4:115–39.
[6] Sukhodolsky DG, BlochMH, Panza KE, Reichow B. Cognitive–behavioral therapy for
anxiety in children with high-functioning autism: a meta-analysis. Pediatrics 2013;
132:e1341–50.
[7] Angelidou A, Alysandratos KD, Asadi S, Zhang B, Francis K, Vasiadi M, et al. Brief re-
port: “allergic symptoms” in children with autism spectrum disorders. More than
meets the eye? J Autism Dev Disord 2011;41:1579–85.
[8] Tuchman R, Rapin I. Epilepsy in autism. Lancet Neurol 2002;1:352–8.
[9] Deykin EY, MacMahon B. The incidence of seizures among children with autistic
symptoms. Am J Psychiatry 1979;136:1310–2.
[10] Volkmar FR, Nelson DS. Seizure disorders in autism. J Am Acad Child Adolesc Psy-
chiatry 1990;29:127–9.
[11] Danielsson S, Gillberg IC, Billstedt E, Gillberg C, Olsson I. Epilepsy in young adults
with autism: a prospective population-based follow-up study of 120 individuals di-
agnosed in childhood. Epilepsia 2005;46:918–23.
[12] Hara H. Autism and epilepsy: a retrospective follow-up study. Brain Dev 2007;29:
486–90.
[13] Sansa G, Carlson C, Doyle W, Weiner HL, Bluvstein J, BarrW, et al. Medically refrac-
tory epilepsy in autism. Epilepsia 2011;52:1071–5.
[14] Gilby KL, O'Brien TJ. Epilepsy, autism, and neurodevelopment: kindling a shared
vulnerability? Epilepsy Behav 2013;26:370–4.
[15] Tuchman R. Autism and social cognition in epilepsy: implications for comprehen-
sive epilepsy care. Curr Opin Neurol 2013;26:214–8.
[16] Rossignol DA, Frye RE. A review of research trends in physiological abnormalities in
autism spectrum disorders: immune dysregulation, inﬂammation, oxidative stress,
mitochondrial dysfunction and environmental toxicant exposures. Mol Psychiatry
2012;17:389–401.
[17] Schaefer GB, Mendelsohn NJ, Professional P, Guidelines C. Clinical genetics evalua-
tion in identifying the etiology of autism spectrum disorders: 2013 guideline revi-
sions. Genet Med 2013;15:399–407.
[18] Tuchman R, Hirtz D, Mamounas LA. NINDS epilepsy and autism spectrum disorders
workshop report. Neurology 2013;81:1630–6.
[19] Murdoch JD, State MW. Recent developments in the genetics of autism spectrum
disorders. Curr Opin Genet Dev 2013;23:310–5.
[20] Frye RE, Sequeira JM, Quadros EV, James SJ, Rossignol DA. Cerebral folate receptor
autoantibodies in autism spectrum disorder. Mol Psychiatry 2013;18:369–81.
[21] Rossignol D, Frye RE. Folate receptor alpha autoimmunity and cerebral folate deﬁ-
ciency in autism spectrum disorders. J Pediatr Biochem 2012;2:263–71.
[22] Tierney E, Bukelis I, Thompson RE, Ahmed K, Aneja A, Kratz L, et al. Abnormalities
of cholesterol metabolism in autism spectrum disorders. Am J Med Genet B
Neuropsychiatr Genet 2006;141B:666–8.
[23] Novarino G, El-Fishawy P, Kayserili H, Meguid NA, Scott EM, Schroth J, et al. Muta-
tions in BCKD-kinase lead to a potentially treatable form of autism with epilepsy.
Science 2012;338:394–7.
[24] Zecavati N, Spence SJ. Neurometabolic disorders and dysfunction in autism spec-
trum disorders. Curr Neurol Neurosci Rep 2009;9:129–36.
[25] Rossignol D, Frye RE. Mitochondrial dysfunction in autism spectrum disorders: a
systematic review and meta-analysis. Mol Psychiatry 2012;17:290–314.
[26] Frye RE, Rossignol DA. Mitochondrial dysfunction can connect the diverse medical
symptoms associated with autism spectrum disorders. Pediatr Res 2011;69:
41R–7R.[27] Frye RE, Rossignol D.Metabolic disorders and abnormalities associatedwith autism
spectrum disorder. J Pediatr Biochem 2012;2:181–91.
[28] Manji H, Kato T, Di Prospero NA, Ness S, Beal MF, Krams M, et al. Impaired mi-
tochondrial function in psychiatric disorders. Nat Rev Neurosci 2012;13:
293–307.
[29] Anglin RE, Garside SL, Tarnopolsky MA, Mazurek MF, Rosebush PI. The psychiatric
manifestations of mitochondrial disorders: a case and review of the literature. J Clin
Psychiatry 2012;73:506–12.
[30] Kang HC, Lee YM, Kim HD. Mitochondrial disease and epilepsy. Brain Dev 2013;35:
757–61.
[31] Kunz WS. The role of mitochondria in epileptogenesis. Curr Opin Neurol 2002;15:
179–84.
[32] Kudin AP, Zsurka G, Elger CE, Kunz WS. Mitochondrial involvement in temporal
lobe epilepsy. Exp Neurol 2009;218:326–32.
[33] Ghanizadeh A, Berk M, Farrashbandi H, Alavi Shoushtari A, Villagonzalo KA.
Targeting themitochondrial electron transport chain in autism, a systematic review
and synthesis of a novel therapeutic approach. Mitochondrion 2013;13:515–9.
[34] Kerr DS. Review of clinical trials for mitochondrial disorders: 1997–2012.
Neurotherapeutics 2013;10:307–19.
[35] Poo-Arguelles P, Arias A, Vilaseca MA, Ribes A, Artuch R, Sans-Fito A, et al. X-linked
creatine transporter deﬁciency in two patients with severe mental retardation and
autism. J Inherit Metab Dis 2006;29:220–3.
[36] Longo N, Ardon O, Vanzo R, Schwartz E, Pasquali M. Disorders of creatine transport
and metabolism. Am J Med Genet C Semin Med Genet 2011;157C:72–8.
[37] Schulze A. Creatine deﬁciency syndromes. Mol Cell Biochem 2003;244:143–50.
[38] vanKarnebeek CD, Stockler S. Treatable inbornerrors ofmetabolism causing intellec-
tual disability: a systematic literature review. Mol Genet Metab 2012;105:368–81.
[39] Anselm IA, Alkuraya FS, Salomons GS, Jakobs C, Fulton AB, Mazumdar M, et al. X-
linked creatine transporter defect: a report on two unrelated boys with a severe
clinical phenotype. J Inherit Metab Dis 2006;29:214–9.
[40] Sikora DM, Pettit-Kekel K, Penﬁeld J, Merkens LS, Steiner RD. The near universal
presence of autism spectrum disorders in children with Smith–Lemli–Opitz syn-
drome. Am J Med Genet A 2006;140:1511–8.
[41] Bukelis I, Porter FD, Zimmerman AW, Tierney E. Smith–Lemli–Opitz syndrome and
autism spectrum disorder. Am J Psychiatry 2007;164:1655–61.
[42] Martin A, Koenig K, Scahill L, Tierney E, Porter FD, Nwokoro NA. Smith–Lemli–Opitz
syndrome. J Am Acad Child Adolesc Psychiatry 2001;40:506–7.
[43] Elias ER, IronsMB, Hurley AD, Tint GS, Salen G. Clinical effects of cholesterol supple-
mentation in six patients with the Smith–Lemli–Opitz syndrome (SLOS). Am J Med
Genet 1997;68:305–10.
[44] Irons M, Elias ER, Abuelo D, Bull MJ, Greene CL, Johnson VP, et al. Treatment of
Smith–Lemli–Opitz syndrome: results of a multicenter trial. Am J Med Genet
1997;68:311–4.
[45] Nwokoro NA, Mulvihill JJ. Cholesterol and bile acid replacement therapy in children
and adults with Smith–Lemli–Opitz (SLO/RSH) syndrome. Am J Med Genet 1997;
68:315–21.
[46] Aneja A, Tierney E. Autism: the role of cholesterol in treatment. Int Rev Psychiatry
2008;20:165–70.
[47] Frustaci A, Neri M, Cesario A, Adams JB, Domenici E, Dalla Bernardina B, et al. Oxi-
dative stress-related biomarkers in autism: systematic review and meta-analyses.
Free Radic Biol Med 2012;52:2128–41.
[48] Boris M, Goldblatt A, Galanko J, James SJ. Association of MTHFR gene variants with
autism. J Am Phys Surg 2004;9:106–8.
[49] Mohammad NS, Jain JM, Chintakindi KP, Singh RP, Naik U, Akella RR. Aberrations in
folate metabolic pathway and altered susceptibility to autism. Psychiatr Genet
2009;19:171–6.
[50] Guo T, Chen H, Liu B, Ji W, Yang C. Methylenetetrahydrofolate reductase polymor-
phisms C677T and risk of autism in the Chinese Han population. Genet Test Mol
Biomarkers 2012;16:968–73.
[51] Schmidt RJ, Tancredi DJ, Ozonoff S, Hansen RL, Hartiala J, Allayee H, et al. Maternal
periconceptional folic acid intake and risk of autism spectrum disorders and devel-
opmental delay in the CHARGE (CHildhood Autism Risks from Genetics and Envi-
ronment) case–control study. Am J Clin Nutr 2012;96:80–9.
[52] Liu X, Solehdin F, Cohen IL, Gonzalez MG, Jenkins EC, Lewis ME, et al. Population-
and family-based studies associate the MTHFR gene with idiopathic autism in sim-
plex families. J Autism Dev Disord 2011;41:938–44.
[53] Goin-Kochel RP, Porter AE, Peters SU, Shinawi M, Sahoo T, Beaudet AL. The MTHFR
677C→T polymorphism and behaviors in children with autism: exploratory geno-
type–phenotype correlations. Autism Res 2009;2:98–108.
[54] Pasca SP, Dronca E, Kaucsar T, Craciun EC, Endreffy E, Ferencz BK, et al. One carbon
metabolism disturbances and the C677T MTHFR gene polymorphism in children
with autism spectrum disorders. J Cell Mol Med 2009;13:4229–38.
[55] James SJ, Melnyk S, Jernigan S, Cleves MA, Halsted CH, Wong DH, et al. Metabolic
endophenotype and related genotypes are associated with oxidative stress in chil-
dren with autism. Am J Med Genet B Neuropsychiatr Genet 2006;141B:947–56.
[56] Pu D, Shen Y, Wu J. Association between MTHFR gene polymorphisms and the risk
of autism spectrum disorders: a meta-analysis. Autism Res 2013;6:384–92.
[57] Adams M, Lucock M, Stuart J, Fardell S, Baker K, Ng X. Preliminary evidence for in-
volvement of the folate gene polymorphism 19 bp deletion-DHFR in occurrence of
autism. Neurosci Lett 2007;422:24–9.
[58] Ramaekers VT, Rothenberg SP, Sequeira JM, Opladen T, Blau N, Quadros EV, et al.
Autoantibodies to folate receptors in the cerebral folate deﬁciency syndrome. N
Engl J Med 2005;352:1985–91.
[59] Ramaekers VT, Blau N, Sequeira JM, Nassogne MC, Quadros EV. Folate receptor au-
toimmunity and cerebral folate deﬁciency in low-functioning autism with neuro-
logical deﬁcits. Neuropediatrics 2007;38:276–81.
155R.E. Frye / Epilepsy & Behavior 47 (2015) 147–157[60] Ramaekers VT, Blau N. Cerebral folate deﬁciency. Dev Med Child Neurol 2004;46:
843–51.
[61] Wollack JB, Makori B, Ahlawat S, Koneru R, Picinich SC, Smith A, et al. Characteriza-
tion of folate uptake by choroid plexus epithelial cells in a rat primary culture
model. J Neurochem 2008;104:1494–503.
[62] Allen RJ, DiMauro S, Coulter DL, Papadimitriou A, Rothenberg SP. Kearns–Sayre
syndrome with reduced plasma and cerebrospinal ﬂuid folate. Ann Neurol 1983;
13:679–82.
[63] Pineda M, Ormazabal A, Lopez-Gallardo E, Nascimento A, Solano A, Herrero MD,
et al. Cerebral folate deﬁciency and leukoencephalopathy caused by amitochondri-
al DNA deletion. Ann Neurol 2006;59:394–8.
[64] Ramaekers VT, Weis J, Sequeira JM, Quadros EV, Blau N. Mitochondrial complex I en-
cephalomyopathyand cerebral 5-methyltetrahydrofolate deﬁciency.Neuropediatrics
2007;38:184–7.
[65] Hasselmann O, Blau N, Ramaekers VT, Quadros EV, Sequeira JM, Weissert M. Cere-
bral folate deﬁciency and CNS inﬂammatory markers in Alpers disease. Mol Genet
Metab 2010;99:58–61.
[66] Perez-Duenas B, Ormazabal A, Toma C, Torrico B, Cormand B, Serrano M, et al. Ce-
rebral folate deﬁciency syndromes in childhood: clinical, analytical, and etiologic
aspects. Arch Neurol 2011;68:615–21.
[67] Garcia-Cazorla A, Quadros EV, Nascimento A, Garcia-SilvaMT, Briones P, Montoya J,
et al. Mitochondrial diseases associated with cerebral folate deﬁciency. Neurology
2008;70:1360–2.
[68] Shoffner J, Hyams L, Langley GN, Cossette S, Mylacraine L, Dale J, et al. Fever plus
mitochondrial disease could be risk factors for autistic regression. J Child Neurol
2010;25:429–34.
[69] Frye RE, Naviaux RK. Autistic disorder with complex IV overactivity: a new mito-
chondrial syndrome. J Pediatr Neurol 2011;9:427–34.
[70] Ramaekers VT, Quadros EV, Sequeira JM. Role of folate receptor autoantibodies in
infantile autism. Mol Psychiatry 2013;18:270–1.
[71] Moretti P, Sahoo T, Hyland K, Bottiglieri T, Peters S, del Gaudio D, et al. Cerebral fo-
late deﬁciencywith developmental delay, autism, and response to folinic acid. Neu-
rology 2005;64:1088–90.
[72] Basura GJ, Hagland SP, Wiltse AM, Gospe Jr SM. Clinical features and the manage-
ment of pyridoxine-dependent and pyridoxine-responsive seizures: review of 63
North American cases submitted to a patient registry. Eur J Pediatr 2009;168:
697–704.
[73] Gupta VK, Mishra D, Mathur I, Singh KK. Pyridoxine-dependent seizures: a case
report and a critical review of the literature. J Paediatr Child Health 2001;37:
592–6.
[74] Mills PB, Struys E, Jakobs C, Plecko B, Baxter P, Baumgartner M, et al. Mutations in
antiquitin in individuals with pyridoxine-dependent seizures. Nat Med 2006;12:
307–9.
[75] Plecko B, Paul K, Paschke E, Stoeckler-Ipsiroglu S, Struys E, Jakobs C, et al. Biochem-
ical and molecular characterization of 18 patients with pyridoxine-dependent epi-
lepsy and mutations of the antiquitin (ALDH7A1) gene. Hum Mutat 2007;28:
19–26.
[76] Gospe SM. Pyridoxine-dependent seizures: ﬁndings from recent studies pose new
questions. Pediatr Neurol 2002;26:181–5.
[77] Gospe Jr SM, Olin KL, Keen CL. Reduced GABA synthesis in pyridoxine-dependent
seizures. Lancet 1994;343:1133–4.
[78] Bankier A, Turner M, Hopkins IJ. Pyridoxine dependent seizures—a wider clinical
spectrum. Arch Dis Child 1983;58:415–8.
[79] Coker SB. Postneonatal vitamin B6-dependent epilepsy. Pediatrics 1992;90:221–3.
[80] Goutieres F, Aicardi J. Atypical presentations of pyridoxine-dependent seizures: a
treatable cause of intractable epilepsy in infants. Ann Neurol 1985;17:117–20.
[81] Haenggeli CA, Girardin E, Paunier L. Pyridoxine-dependent seizures, clinical and
therapeutic aspects. Eur J Pediatr 1991;150:452–5.
[82] Krishnamoorthy KS. Pyridoxine-dependency seizure: report of a rare presentation.
Ann Neurol 1983;13:103–4.
[83] Mikati MA, Trevathan E, Krishnamoorthy KS, Lombroso CT. Pyridoxine-dependent
epilepsy: EEG investigations and long-term follow-up. Electroencephalogr Clin
Neurophysiol 1991;78:215–21.
[84] Baxter P. Epidemiology of pyridoxine dependent and pyridoxine responsive sei-
zures in the UK. Arch Dis Child 1999;81:431–3.
[85] Martineau J, Barthelemy C, Garreau B, Lelord G. Vitamin B6, magnesium, and com-
bined B6-Mg: therapeutic effects in childhood autism. Biol Psychiatry 1985;20:
467–78.
[86] Mousain-Bosc M, Roche M, Polge A, Pradal-Prat D, Rapin J, Bali JP. Improvement of
neurobehavioral disorders in children supplemented with magnesium-vitamin B6.
II. Pervasive developmental disorder-autism. Magnes Res 2006;19:53–62.
[87] Lelord G, Callaway E, Muh JP. Clinical and biological effects of high doses of vi-
tamin B6 and magnesium on autistic children. Acta Vitaminol Enzymol 1982;
4:27–44.
[88] Lelord G, Muh JP, Barthelemy C, Martineau J, Garreau B, Callaway E. Effects of pyr-
idoxine and magnesium on autistic symptoms—initial observations. J Autism Dev
Disord 1981;11:219–30.
[89] Nye C, Brice A. Combined vitamin B6–magnesium treatment in autism spectrum
disorder. Cochrane Database Syst Rev 2005:CD003497.
[90] Rossignol DA. Novel and emerging treatments for autism spectrum disorders: a
systematic review. Ann Clin Psychiatry 2009;21:213–36.
[91] Burd L, Stenehjem A, Franceschini LA, Kerbeshian J. A 15-year follow-up of a boy
with pyridoxine (vitamin B6)-dependent seizures with autism, breath holding,
and severe mental retardation. J Child Neurol 2000;15:763–5.
[92] Zaffanello M, Zamboni G, Fontana E, Zoccante L, Tato L. A case of partial biotinidase
deﬁciency associated with autism. Child Neuropsychol 2003;9:184–8.[93] Celestino-Soper PB, Violante S, Crawford EL, Luo R, Lionel AC, Delaby E, et al. A com-
mon X-linked inborn error of carnitine biosynthesis may be a risk factor for
nondysmorphic autism. Proc Natl Acad Sci U S A 2012;109:7974–81.
[94] Filipek PA, Juranek J, Nguyen MT, Cummings C, Gargus JJ. Relative carnitine deﬁ-
ciency in autism. J Autism Dev Disord 2004;34:615–23.
[95] Palmieri L, Persico AM. Mitochondrial dysfunction in autism spectrum disorders:
cause or effect? Biochim Biophys Acta 2010;1797:1130–7.
[96] Frye RE, Melnyk S, Macfabe DF. Unique acyl-carnitine proﬁles are potential bio-
markers for acquired mitochondrial disease in autism spectrum disorder. Transl
Psychiatry 2013;3:e220.
[97] Macfabe DF. Short-chain fatty acid fermentation products of the gut microbiome:
implications in autism spectrum disorders. Microb Ecol Health Dis 2012:23.
[98] Jakobs C, Bojasch M, Monch E, Rating D, Siemes H, Hanefeld F. Urinary excretion of
gamma-hydroxybutyric acid in a patient with neurological abnormalities. The
probability of a new inborn error of metabolism. Clin Chim Acta 1981;111:169–78.
[99] Pearl PL, Gibson KM, Quezado Z, Dustin I, Taylor J, Trzcinski S, et al. Decreased
GABA-A binding on FMZ-PET in succinic semialdehyde dehydrogenase deﬁciency.
Neurology 2009;73:423–9.
[100] Knerr I, Gibson KM, Jakobs C, Pearl PL. Neuropsychiatric morbidity in adolescent
and adult succinic semialdehyde dehydrogenase deﬁciency patients. CNS Spectr
2008;13:598–605.
[101] Pearl PL, Gibson KM. Clinical aspects of the disorders of GABA metabolism in chil-
dren. Curr Opin Neurol 2004;17:107–13.
[102] Pearl PL, Novotny EJ, Acosta MT, Jakobs C, Gibson KM. Succinic semialdehyde dehy-
drogenase deﬁciency in children and adults. Ann Neurol 2003;54(Suppl. 6):
S73–80.
[103] Pearl PL, Gibson KM, Acosta MT, Vezina LG, TheodoreWH, Rogawski MA, et al. Clin-
ical spectrum of succinic semialdehyde dehydrogenase deﬁciency. Neurology
2003;60:1413–7.
[104] Jurecka A, Zikanova M, Tylki-Szymanska A, Krijt J, Bogdanska A, Gradowska W,
et al. Clinical, biochemical and molecular ﬁndings in seven Polish patients with
adenylosuccinate lyase deﬁciency. Mol Genet Metab 2008;94:435–42.
[105] Spiegel EK, Colman RF, Patterson D. Adenylosuccinate lyase deﬁciency. Mol Genet
Metab 2006;89:19–31.
[106] Gitiaux C, Ceballos-Picot I, Marie S, Valayannopoulos V, Rio M, Verrieres S, et al.
Misleading behavioural phenotype with adenylosuccinate lyase deﬁciency. Eur J
Hum Genet 2009;17:133–6.
[107] Page T. Metabolic approaches to the treatment of autism spectrum disorders. J Au-
tism Dev Disord 2000;30:463–9.
[108] Page T, Yu A, Fontanesi J, Nyhan WL. Developmental disorder associated with
increased cellular nucleotidase activity. Proc Natl Acad Sci U S A 1997;94:
11601–6.
[109] Williams RA, Mamotte CD, Burnett JR. Phenylketonuria: an inborn error of phenyl-
alanine metabolism. Clin Biochem Rev 2008;29:31–41.
[110] Baieli S, Pavone L, Meli C, Fiumara A, Coleman M. Autism and phenylketonuria. J
Autism Dev Disord 2003;33:201–4.
[111] Martynyuk AE, Ucar DA, Yang DD, Norman WM, Carney PR, Dennis DM, et al. Epi-
lepsy in phenylketonuria: a complex dependence on serum phenylalanine levels.
Epilepsia 2007;48:1143–50.
[112] Gross PT, Berlow S, Schuett VE, Fariello RG. EEG in phenylketonuria. Attempt to es-
tablish clinical importance of EEG changes. Arch Neurol 1981;38:122–6.
[113] Boccuto L, Chen CF, Pittman AR, Skinner CD, McCartney HJ, Jones K, et al. Decreased
tryptophan metabolism in patients with autism spectrum disorders. Mol Autism
2013;4:16.
[114] Egawa J, Watanabe Y, Endo T, Someya T. Association of rs2129575 in the trypto-
phan hydroxylase 2 gene with clinical phenotypes of autism spectrum disorders.
Psychiatry Clin Neurosci 2013;67:457–8.
[115] Yang SY, Yoo HJ, Cho IH, Park M, Kim SA. Association with tryptophan hydroxylase
2 gene polymorphisms and autism spectrum disorders in Korean families. Neurosci
Res 2012;73:333–6.
[116] Bragatti JA, Bandeira IC, de Carvalho AM, Abujamra AL, Leistner-Segal S, Bianchin
MM. Tryptophan hydroxylase 2 (TPH2) gene polymorphisms and psychiatric co-
morbidities in temporal lobe epilepsy. Epilepsy Behav 2014;32:59–63.
[117] Arbatova J, D'Amato E, Vaarmann A, Zharkovsky A, Reeben M. Reduced serotonin
and 3-hydroxyanthranilic acid levels in serum of cystatin B-deﬁcient mice, a
model system for progressive myoclonus epilepsy. Epilepsia 2005;46(Suppl. 5):
49–51.
[118] Vaarmann A, Kaasik A, Zharkovsky A. Altered tryptophan metabolism in the brain
of cystatin B-deﬁcient mice: a model system for progressive myoclonus epilepsy.
Epilepsia 2006;47:1650–4.
[119] Gorker I, TuzunU. Autistic-like ﬁndings associatedwith a urea cycle disorder in a 4-
year-old girl. J Psychiatry Neurosci 2005;30:133–5.
[120] SerranoM,Martins C, Perez-Duenas B, Gomez-Lopez L, Murgui E, Fons C, et al. Neu-
ropsychiatric manifestations in late-onset urea cycle disorder patients. J Child
Neurol 2010;25:352–8.
[121] Braissant O. Current concepts in the pathogenesis of urea cycle disorders. Mol
Genet Metab 2010;100(Suppl. 1):S3–S12.
[122] Rossignol DA, Frye RE. Mitochondrial dysfunction in autism spectrum disorders: a
systematic review and meta-analysis. Mol Psychiatry 2012;17:290–314.
[123] Frye RE. Biomarker of abnormal energy metabolism in children with autism spec-
trum disorder. N Am J Med Sci 2012;5:141–7.
[124] Giulivi C, Zhang YF, Omanska-Klusek A, Ross-Inta C,Wong S, Hertz-Picciotto I, et al.
Mitochondrial dysfunction in autism. JAMA 2010;304:2389–96.
[125] Napoli E, Wong S, Hertz-Picciotto I, Giulivi C. Deﬁcits in bioenergetics and impaired
immune response in granulocytes from children with autism. Pediatrics 2014;133:
e1405–10.
156 R.E. Frye / Epilepsy & Behavior 47 (2015) 147–157[126] Rose S, Melnyk S, Pavliv O, Bai S, Nick TG, Frye RE, et al. Evidence of oxidative dam-
age and inﬂammation associated with low glutathione redox status in the autism
brain. Transl Psychiatry 2012;2:e134.
[127] Chauhan A, Gu F, Essa MM,Wegiel J, Kaur K, BrownWT, et al. Brain region-speciﬁc
deﬁcit in mitochondrial electron transport chain complexes in children with au-
tism. J Neurochem 2011;117:209–20.
[128] Tang G, Gutierrez Rios P, Kuo SH, Akman HO, Rosoklija G, Tanji K, et al. Mitochon-
drial abnormalities in temporal lobe of autistic brain. Neurobiol Dis 2013;54:
349–61.
[129] Anitha A, Nakamura K, Thanseem I, Yamada K, Iwayama Y, Toyota T, et al. Brain
region-speciﬁc altered expression and association of mitochondria-related genes
in autism. Mol Autism 2012;3:12.
[130] Anitha A, Nakamura K, Thanseem I, Matsuzaki H, Miyachi T, Tsujii M, et al. Down-
regulation of the expression of mitochondrial electron transport complex genes in
autism brains. Brain Pathol 2013;23:294–302.
[131] Rossignol DA, Frye RE. Evidence linking oxidative stress, mitochondrial dysfunc-
tion, and inﬂammation in the brain of individuals with autism. Front Physiol
2014;5:150.
[132] Kriaucionis S, Paterson A, Curtis J, Guy J, Macleod N, Bird A. Gene expression anal-
ysis exposes mitochondrial abnormalities in a mouse model of Rett syndrome. Mol
Cell Biol 2006;26:5033–42.
[133] Graf WD,Marin-Garcia J, Gao HG, Pizzo S, Naviaux RK, Markusic D, et al. Autism as-
sociated with the mitochondrial DNA G8363A transfer RNA(Lys) mutation. J Child
Neurol 2000;15:357–61.
[134] Rose S, Frye RE, Slattery J, Wynne R, Tippett M, Pavliv O, et al. Oxidative stress in-
duces mitochondrial dysfunction in a subset of autism lymphoblastoid cell lines
in a well-matched case control cohort. PLoS One 2014;9:e85436.
[135] Rose S, Frye RE, Slattery J, Wynne R, Tippett M, Melnyk S, et al. Oxidative stress in-
duces mitochondrial dysfunction in a subset of autistic lymphoblastoid cell lines.
Transl Psychiatry 2014;4:e377.
[136] Minshew NJ, Goldstein G, Dombrowski SM, Panchalingam K, Pettegrew JW. A pre-
liminary 31PMRS study of autism: evidence for undersynthesis and increased deg-
radation of brain membranes. Biol Psychiatry 1993;33:762–73.
[137] Mostafa GA, El-Gamal HA, El-Wakkad ASE, El-Shorbagy OE, HamzaMM. Polyunsat-
urated fatty acids, carnitine and lactate as biological markers of brain energy in au-
tistic children. Int J Child Neuropsychiatry 2005;2:179–88.
[138] Frye RE, Delatorre R, Taylor H, Slattery J, Melnyk S, Chowdhury N, et al. Redox me-
tabolism abnormalities in autistic children associated with mitochondrial disease.
Transl Psychiatry 2013;3:e273.
[139] Fillano JJ, Goldenthal MJ, Rhodes CH, Marin-Garcia J. Mitochondrial dysfunction in
patients with hypotonia, epilepsy, autism, and developmental delay: HEADD syn-
drome. J Child Neurol 2002;17:435–9.
[140] Filipek PA, Juranek J, Smith M, Mays LZ, Ramos ER, Bocian M, et al. Mitochondrial
dysfunction in autistic patients with 15q inverted duplication. Ann Neurol 2003;
53:801–4.
[141] Poling JS, Frye RE, Shoffner J, Zimmerman AW. Developmental regression and mi-
tochondrial dysfunction in a child with autism. J Child Neurol 2006;21:170–2.
[142] Grosser E, Hirt U, Janc OA, Menzfeld C, Fischer M, Kempkes B, et al. Oxidative bur-
den and mitochondrial dysfunction in a mouse model of Rett syndrome. Neurobiol
Dis 2012;48:102–14.
[143] Gibson JH, Slobedman B, NH K, Williamson SL, Minchenko D, El-Osta A, et al. Down-
stream targets of methyl CpG binding protein 2 and their abnormal expression in the
frontal cortex of the human Rett syndrome brain. BMC Neurosci 2010;11:53.
[144] Condie J, Goldstein J, Wainwright MS. Acquired microcephaly, regression of mile-
stones, mitochondrial dysfunction, and episodic rigidity in a 46, XY male with a
de novo MECP2 gene mutation. J Child Neurol 2010;25:633–6.
[145] Napoli E, Ross-Inta C,Wong S, Hung C, Fujisawa Y, Sakaguchi D, et al. Mitochondrial
dysfunction in Pten haplo-insufﬁcient mice with social deﬁcits and repetitive be-
havior: interplay between Pten and p53. PLoS One 2012;7:e42504.
[146] Frye RE. Mitochondrial disease in 22q13 duplication syndrome. J Child Neurol
2012;27:942–9.
[147] Frye RE. 15q11.2-13 duplication, mitochondrial dysfunction, and developmental
disorders. J Child Neurol 2009;24:1316–20.
[148] Su H, Fan W, Coskun PE, Vesa J, Gold JA, Jiang YH, et al. Mitochondrial dysfunction
in CA1 hippocampal neurons of the UBE3A deﬁcient mouse model for Angelman
syndrome. Neurosci Lett 2011;487:129–33.
[149] Schuelke M, Krude H, Finckh B, Mayatepek E, Janssen A, Schmelz M, et al. Septo-
optic dysplasia associated with a new mitochondrial cytochrome b mutation.
Ann Neurol 2002;51:388–92.
[150] Pagano G, Castello G. Oxidative stress and mitochondrial dysfunction in Down syn-
drome. Adv Exp Med Biol 2012;724:291–9.
[151] Pallardo FV, Lloret A, Lebel M, d'Ischia M, Cogger VC, Le Couteur DG, et al.
Mitochondrial dysfunction in some oxidative stress-related genetic diseases:
ataxia–telangiectasia, Down syndrome, Fanconi anaemia and Werner syndrome.
Biogerontology 2010;11:401–19.
[152] De Angelis M, PiccoloM, Vannini L, Siragusa S, De GiacomoA, Serrazzanetti DI, et al.
Fecal microbiota and metabolome of children with autism and pervasive develop-
mental disorder not otherwise speciﬁed. PLoS One 2013;8:e76993.
[153] Macfabe D. Autism: metabolism, mitochondria, and the microbiome. Glob Adv
Health Med 2013;2:52–66.
[154] Ames III A. CNS energy metabolism as related to function. Brain Res Brain Res Rev
2000;34:42–68.
[155] Mattson MP, Liu D. Energetics and oxidative stress in synaptic plasticity and neuro-
degenerative disorders. Neuromolecular Med 2002;2:215–31.
[156] Chen H, Chan DC. Mitochondrial dynamics—fusion, ﬁssion, movement, and
mitophagy—in neurodegenerative diseases. Hum Mol Genet 2009;18:R169–76.[157] Li Z, Okamoto K, Hayashi Y, Sheng M. The importance of dendritic mitochondria in
the morphogenesis and plasticity of spines and synapses. Cell 2004;119:873–87.
[158] Anderson MP, Hooker BS, Herbert MR. Bridging from cells to cognition in autism
pathophysiology: biological pathways to defective brain function and plasticity.
Am J Biochem Biotechnol 2008;4:167–76.
[159] Orekhova EV, Stroganova TA, Nygren G, Tsetlin MM, Posikera IN, Gillberg C, et al.
Excess of high frequency electroencephalogram oscillations in boys with autism.
Biol Psychiatry 2007;62:1022–9.
[160] Herlenius E, Lagercrantz H. Development of neurotransmitter systems during crit-
ical periods. Exp Neurol 2004;190(Suppl. 1):S8–S21.
[161] Huttenlocher PR, Dabholkar AS. Regional differences in synaptogenesis in human
cerebral cortex. J Comp Neurol 1997;387:167–78.
[162] Groeschel S, Vollmer B, King MD, Connelly A. Developmental changes in cerebral
grey and white matter volume from infancy to adulthood. Int J Dev Neurosci
2010;28:481–9.
[163] Rowley NM, Madsen KK, Schousboe A, Steve White H. Glutamate and GABA syn-
thesis, release, transport andmetabolism as targets for seizure control. Neurochem
Int 2012;61:546–58.
[164] Lason W, Chlebicka M, Rejdak K. Research advances in basic mechanisms of sei-
zures and antiepileptic drug action. Pharmacol Rep 2013;65:787–801.
[165] Pastore A, Federici G, Bertini E, Piemonte F. Analysis of glutathione: implication in
redox and detoxiﬁcation. Clin Chim Acta 2003;333:19–39.
[166] Aguiar CC, Almeida AB, Araujo PV, de Abreu RN, Chaves EM, do Vale OC, et al.
Oxidative stress and epilepsy: literature review. Oxid Med Cell Longev 2012;
2012:795259.
[167] Grosso C, Valentao P, Ferreres F, Andrade PB. The use of ﬂavonoids in central ner-
vous system disorders. Curr Med Chem 2013;20:4694–719.
[168] Azam F, PrasadMV, Thangavel N. Targeting oxidative stress component in the ther-
apeutics of epilepsy. Curr Top Med Chem 2012;12:994–1007.
[169] Milder J, Patel M. Modulation of oxidative stress and mitochondrial function by the
ketogenic diet. Epilepsy Res 2012;100:295–303.
[170] Scheck AC, AbdelwahabMG, Fenton KE, Stafford P. The ketogenic diet for the treat-
ment of glioma: insights from genetic proﬁling. Epilepsy Res 2012;100:327–37.
[171] Xu D,Miller SD, Koh S. Immunemechanisms in epileptogenesis. Front Cell Neurosci
2013;7:195.
[172] Gesundheit B, Rosenzweig JP, Naor D, Lerer B, Zachor DA, Prochazka V, et al. Immu-
nological and autoimmune considerations of autism spectrum disorders. J
Autoimmun 2013;44:1–7.
[173] Connolly AM, Chez MG, Pestronk A, Arnold ST, Mehta S, Deuel RK. Serum autoan-
tibodies to brain in Landau–Kleffner variant, autism, and other neurologic disor-
ders. J Pediatr 1999;134:607–13.
[174] Connolly AM, Chez M, Streif EM, Keeling RM, Golumbek PT, Kwon JM, et al. Brain-
derived neurotrophic factor and autoantibodies to neural antigens in sera of chil-
dren with autistic spectrum disorders, Landau–Kleffner syndrome, and epilepsy.
Biol Psychiatry 2006;59:354–63.
[175] Derecki NC, Cronk JC, Lu Z, Xu E, Abbott SB, Guyenet PG, et al. Wild-type microglia
arrest pathology in a mouse model of Rett syndrome. Nature 2012;484:105–9.
[176] Boulanger LM, Shatz CJ. Immune signalling in neural development, synaptic plastic-
ity and disease. Nat Rev Neurosci 2004;5:521–31.
[177] Gargus JJ. Genetic calcium signaling abnormalities in the central nervous system:
seizures, migraine, and autism. Ann N Y Acad Sci 2009;1151:133–56.
[178] Schmunk G, Gargus JJ. Channelopathy pathogenesis in autism spectrum disorders.
Front Genet 2013:4.
[179] Splawski I, Timothy KW, Sharpe LM, Decher N, Kumar P, Bloise R, et al. Ca(V)1.2
calcium channel dysfunction causes a multisystem disorder including arrhythmia
and autism. Cell 2004;119:19–31.
[180] Rizzuto R, Bernardi P, Pozzan T. Mitochondria as all-round players of the calcium
game. J Physiol 2000;529(Pt 1):37–47.
[181] Kaufman RJ, Malhotra JD. Calcium trafﬁcking integrates endoplasmic reticulum
function with mitochondrial bioenergetics. Biochim Biophys Acta 1843;2014:
2233–9.
[182] van Vliet AR, Verfaillie T, Agostinis P. New functions of mitochondria associated
membranes in cellular signaling. Biochim Biophys Acta 1843;2014:2253–62.
[183] Geier DA, Kern JK, Davis G, King PG, Adams JB, Young JL, et al. A prospective double-
blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders.
Med Sci Monit 2011;17:I15–23.
[184] Fahmy SF, El-hamamsy MH, Zaki OK, Badary OA. L-Carnitine supplementation im-
proves the behavioral symptoms in autistic children. Res Autism Spectr Disord
2013;7:159–66.
[185] Pastural E, Ritchie S, Lu Y, Jin W, Kavianpour A, Khine Su-Myat K, et al. Novel
plasma phospholipid biomarkers of autism: mitochondrial dysfunction as a
putative causative mechanism. Prostaglandins Leukot Essent Fatty Acids
2009;81:253–64.
[186] Gargus JJ, Lerner MA. Familial autism with primary carnitine deﬁciency, sudden
death, hypotonia and hypochromic anemia. Am J Hum Genet 1997;61:A98.
[187] Gargus JJ, Imtiaz F. Mitochondrial energy-deﬁcient endophenotype in autism. Am J
Biochem Biotech 2008;4:198–207.
[188] Ezugha H, Goldenthal M, Valencia I, Anderson CE, Legido A, Marks H. 5q14.3 dele-
tion manifesting as mitochondrial disease and autism: case report. J Child Neurol
2010;25:1232–5.
[189] Adams JB, Holloway C. Pilot study of a moderate dose multivitamin/mineral sup-
plement for children with autistic spectrum disorder. J Altern Complement Med
2004;10:1033–9.
[190] Adams JB, Audhya T, McDonough-Means S, Rubin RA, Quig D, Geis E, et al. Effect of
a vitamin/mineral supplement on children and adults with autism. BMC Pediatr
2011;11:111.
157R.E. Frye / Epilepsy & Behavior 47 (2015) 147–157[191] Dolske MC, Spollen J, McKay S, Lancashire E, Tolbert L. A preliminary trial of ascor-
bic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psy-
chiatry 1993;17:765–74.
[192] Frye RE, Melnyk S, Fuchs G, Reid T, Jernigan S, Pavliv O, et al. Effectiveness of
methylcobalamin and folinic acid treatment on adaptive behavior in children
with autistic disorder is related to glutathione redox status. Autism Res Treat
2013;2013:609705.
[193] James SJ, Melnyk S, Fuchs G, Reid T, Jernigan S, Pavliv O, et al. Efﬁcacy of
methylcobalamin and folinic acid treatment on glutathione redox status in chil-
dren with autism. Am J Clin Nutr 2009;89:425–30.
[194] Nakano K, Noda N, Tachikawa E, Urano MAN, Takazawa M, Nakayama T, et al. A
preliminary study of methylcobalamin therapy in autism. J Tokyo Women's Med
Univ 2005;75:64–9.
[195] Ghanizadeh A, Derakhshan N. N-acetylcysteine for treatment of autism, a case re-
port. J Res Med Sci 2012;17:985–7.
[196] Ghanizadeh A, Moghimi-Sarani E. A randomized double blind placebo controlled
clinical trial of N-acetylcysteine added to risperidone for treating autistic disorders.
BMC Psychiatry 2013;13:196.
[197] Hardan AY, Fung LK, Libove RA, Obukhanych TV, Nair S, Herzenberg LA, et al. A ran-
domized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol
Psychiatry 2012;71:956–61.
[198] Gvozdjakova A, Kucharska J, Ostatnikova D, Babinska K, Nakladal D, Crane FL.
Ubiquinol improves symptoms in children with autism. Oxid Med Cell Longev
2014;2014:798957.
[199] Chez MG, Buchanan CP, Aimonovitch MC, Becker M, Schaefer K, Black C,
et al. Double-blind, placebo-controlled study of L-carnosine supplementa-
tion in children with autistic spectrum disorders. J Child Neurol 2002;17:
833–7.
[200] Foley KA, Ossenkopp KP, Kavaliers M, Macfabe DF. Pre- and neonatal exposure to
lipopolysaccharide or the enteric metabolite, propionic acid, alters development
and behavior in adolescent rats in a sexually dimorphic manner. PLoS One 2014;
9:e87072.
[201] Foley KA, Macfabe DF, Vaz A, Ossenkopp KP, Kavaliers M. Sexually dimorphic ef-
fects of prenatal exposure to propionic acid and lipopolysaccharide on socialbehavior in neonatal, adolescent, and adult rats: implications for autism spectrum
disorders. Int J Dev Neurosci 2014;39:68–78.
[202] Ahn Y, NarousM, Tobias R, Rho JM, Mychasiuk R. The ketogenic diet modiﬁes social
and metabolic alterations identiﬁed in the prenatal valproic acid model of autism
spectrum disorder. Dev Neurosci 2014;36:371–80.
[203] Gilby KL. A new rat model for vulnerability to epilepsy and autism spectrum disor-
ders. Epilepsia 2008;49(Suppl. 8):108–10.
[204] Ruskin DN, Svedova J, Cote JL, Sandau U, Rho JM, Kawamura Jr M, et al. Ketogenic
diet improves core symptoms of autism in BTBR mice. PLoS One 2013;8:e65021.
[205] Mantis JG, Meidenbauer JJ, Zimick NC, Centeno NA, Seyfried TN. Glucose reduces
the anticonvulsant effects of the ketogenic diet in EL mice. Epilepsy Res 2014;
108:1137–44.
[206] Munnich A, Rotig A, Chretien D, Cormier V, Bourgeron T, Bonnefont JP, et al. Clinical
presentation of mitochondrial disorders in childhood. J Inherit Metab Dis 1996;19:
521–7.
[207] Nissenkorn A, Zeharia A, Lev D, Watemberg N, Fattal-Valevski A, Barash V, et al.
Neurologic presentations of mitochondrial disorders. J Child Neurol 2000;15:44–8.
[208] Zeviani M, Di Donato S. Mitochondrial disorders. Brain 2004;127:2153–72.
[209] ChauhanA, ChauhanV. Oxidative stress in autism. Pathophysiology2006;13:171–81.
[210] Rossignol DA, Genuis SJ, Frye RE. Environmental toxicants and autism spectrum
disorders: a systematic review. Transl Psychiatry 2014;4:e360.
[211] Sandler RH, Finegold SM, Bolte ER, Buchanan CP, Maxwell AP, Vaisanen ML, et al.
Short-term beneﬁt from oral vancomycin treatment of regressive-onset autism. J
Child Neurol 2000;15:429–35.
[212] Finegold SM, Molitoris D, Song Y, Liu C, Vaisanen ML, Bolte E, et al. Gastrointestinal
microﬂora studies in late-onset autism. Clin Infect Dis 2002;35:S6–S16.
[213] Morava E, van den Heuvel L, Hol F, de Vries MC, Hogeveen M, Rodenburg RJ, et al.
Mitochondrial disease criteria: diagnostic applications in children. Neurology 2006;
67:1823–6.
[214] Smeitink JA. Mitochondrial disorders: clinical presentation and diagnostic di-
lemmas. J Inherit Metab Dis 2003;26:199–207.
[215] Ramaekers VT, Sequeira JM, Artuch R, Blau N, Temudo T, Ormazabal A, et al. Folate
receptor autoantibodies and spinal ﬂuid 5-methyltetrahydrofolate deﬁciency in
Rett syndrome. Neuropediatrics 2007;38:179–83.
